Pretreatment with FK506 improves survival rate and gas exchange in canine model of acute lung injury

T. Koshika, A. Ishizaka, I. Nagatomi, Y. Sudo, N. Hasegawa, T. Goto

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)


The novel effects of FK506 on shock induced by lipopolysaccharide and phorbol myristate acetate (LPS/PMA) were studied using beagles. Five groups were studied: endotoxin shock control group (both 0.5 mg/kg of LPS and 30 μg/kg of PMA, n = 6); methylprednisolone-treated endotoxin shock group (n = 5); FK506-treated endotoxin shock groups in which intravenous infusions of FK506 at 2.5 μg/kg/h (low dose, n 5), 8 μg/kg/h (medium dose, n = 5), and 25 μg/kg/h (high dose, n = 5) were administered, in the control group, the survival rate was 33%. Also, arterial hypoxemia, systemic hypotension, and marked increases in pulmonary vascular resistance (PVR) and wet-to-dry weight ratio (W/D) were observed. FK506 treatment at both medium and high doses significantly attenuated these LPS/PMA-induced physiological changes, and the survival rates were 80 and 100%, respectively. On the other hand, in the methylprednisolone group, no obvious effects were observed. The present study suggests that FK506 could have prophylactic potential against acute lung injury in endotoxin shock.

Original languageEnglish
Pages (from-to)79-84
Number of pages6
JournalAmerican journal of respiratory and critical care medicine
Issue number1
Publication statusPublished - 2001

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine


Dive into the research topics of 'Pretreatment with FK506 improves survival rate and gas exchange in canine model of acute lung injury'. Together they form a unique fingerprint.

Cite this